Loading…
Lumimeds was selling unapproved and misbranded compounded semaglutide and tirzepatide products online in violation of federal drug law. The company made false or misleading claims suggesting its compounded drugs were equivalent to FDA-approved brand-name GLP-1 medications, when in fact compounded drugs are not FDA-approved. These deceptive marketing practices on the company's website violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, which prohibit false or misleading labeling and promotion of compounded drugs.